Doctor Arcomita Doina

21/04/2026

is associated with higher risk for 12 types and accounts for approximately 10% of annual new cancer cases in the US.

Excess adiposity promotes cancer development through inflammation, altered hormone production, disrupted immune function, genomic instability, and gut microbiome changes.

Weight loss interventions, including bariatric surgery and glucagon-like peptide 1 receptor agonists ( -1 RAs), have been linked to modest reductions in obesity-associated cancer risk, although >10% weight loss may be necessary for measurable benefit.

📄 This Review summarizes the primary biological pathways connecting obesity and cancer development.

https://ja.ma/4cVUp9w

11/04/2026

26/02/2026

07/01/2026

Globally, metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most common chronic liver disease, affecting up to one in three people in the general population.

A new Review summarises recent breakthroughs, potential future developments, and discusses the key challenges around selecting appropriate treatment avenues for patients.

Read in full via the link in comments 💬

👇 Figure: Summary of mechanisms of action targeted for MASH therapy.

04/01/2026

and effectively target and GIP receptors for obesity treatment, with future therapies exploring further receptor targeting for improved outcomes.

https://ja.ma/45Dk5Um

27/12/2025

17/12/2025

11/10/2025

50 mg of oral daily was associated with body weight reduction and improved cardiometabolic risk factors in East Asian adults with overweight or , with or without type 2 . https://ja.ma/47fYGll

19/09/2025

Integrating lifestyle factors like diet and physical activity with receptor agonists is essential for managing symptoms, maintaining nutrition, preserving lean mass, and promoting regular physical activity. https://ja.ma/4n9MFmH

29/07/2025

Physicians detail five practical measures to optimize GLP-1 therapy and prevent muscle loss in patients undergoing weight reduction. http://ms.spr.ly/6187sHcwf

25/06/2025

Semaglutide (Wegovy) is associated with a 41% reduction in the risk for major adverse cardiovascular events (MACEs) within 6 months of initiation — well before patients achieve substantial weight loss or reach the full 2.4 mg weekly dose — according to new data from the SELECT trial. http://ms.spr.ly/6186SbBuy

08/06/2025

Continuing metformin throughout the first trimester in women with polycystic o***y syndrome shows potential to reduce miscarriage risk and increase clinical pregnancy rates. http://ms.spr.ly/6184SW4Yp